ASRS 2024: Real-world safety and efficacy of aflibercept 8 mg in the treatment nAMD
Listen to Deepak Sambhara, MD, present the findings from a real-world case study that measured the safety and efficacy of Aflibercept 8 mg for treating nonexudative AMD at ASRS 2024.
Listen to Deepak Sambhara, MD, present the findings from a real-world case study that measured the safety and efficacy of Aflibercept 8 mg for treating nonexudative AMD at ASRS 2024. Dr. Sambhara states that patients who were switched to aflibercept 8 mg showed improvements both in visual acuity and anatomically as indexed by OCT (SPECTRALIS, Heidelberg Engineering) with greater durability.
Deepak Sambhara, MD at ASR
Image courtesy: Ophthalmology Times
For more valuable information about our products, educational offerings, learning materials and events
Subscribe to our Newsletter or Contact us